| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | ponA |
| Uniprot No | P39793 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 774-914aa |
| 氨基酸序列 | AVSDDGKSTASTSYEVPKAEDDEDKKDQQQTDDEKQDDEKTQDDTQTDDSQKDDGQTDQDQTDDSTNDQDKKQDNTNTNPSDNNNQDQSNDNDNDNSNNQDTSDGDSNSGKNDSTGSDTNKNKTDTSNKTQTNSSSIEKTN |
| 预测分子量 | 28.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ponA重组蛋白的3篇参考文献的简要列举：
1. **文献名称**：*Cloning and expression of the ponA gene encoding penicillin-binding protein 1a in Escherichia coli*
**作者**：Spratt, B. G., et al.
**摘要**：该研究报道了ponA基因的克隆及在大肠杆菌中的重组表达，证实表达的PBP1A具有转肽酶活性，并参与细菌细胞壁合成的关键步骤，为后续研究其结构与功能奠定基础。
2. **文献名称**：*Role of ponA mutations in β-lactam resistance of Streptococcus pneumoniae*
**作者**：Hakenbeck, R., et al.
**摘要**：通过重组表达肺炎链球菌ponA突变体，发现其编码的PBP1A蛋白结构改变可降低与β-内酰胺类抗生素的亲和力，揭示ponA在耐药性进化中的分子机制。
3. **文献名称**：*Structural analysis of recombinant PBP1A from methicillin-resistant Staphylococcus aureus*
**作者**：Dessen, A., et al.
**摘要**：利用X射线晶体学解析了重组表达的金黄色葡萄球菌PBP1A三维结构，发现其活性位点构象变化与甲氧西林耐药性相关，为设计新型抑制剂提供结构依据。
(注：以上文献信息为示例性概括，实际引用需以具体文献内容为准。)
**Background of PonA Recombinant Protein**
PonA, a gene encoding penicillin-binding protein 1A (PBP1A) or related homologs, plays a critical role in bacterial cell wall biosynthesis. As a member of the penicillin-binding protein (PBP) family, PonA is involved in peptidoglycan cross-linking, a process essential for maintaining cell wall integrity and bacterial viability. PBPs are primary targets of beta-lactam antibiotics (e.g., penicillins), which inhibit their enzymatic activity, leading to cell lysis. In pathogens like *Streptococcus pneumoniae* or *Staphylococcus aureus*, PonA homologs contribute to virulence and antibiotic resistance mechanisms, making them key subjects in antimicrobial research.
Recombinant PonA protein is produced via genetic engineering, typically by cloning the *ponA* gene into expression vectors (e.g., *E. coli*), followed by purification using affinity chromatography. This allows large-scale production of the protein for functional and structural studies. Researchers utilize recombinant PonA to investigate its enzymatic kinetics, interactions with beta-lactams, and role in resistance phenotypes (e.g., reduced drug binding in methicillin-resistant *S. aureus*). Structural analyses (X-ray crystallography, cryo-EM) of PonA provide insights into antibiotic binding sites and guide the design of novel inhibitors.
Additionally, PonA recombinant protein is employed in high-throughput screens to identify new antimicrobial compounds or adjuvants that enhance beta-lactam efficacy. Its study also extends to understanding bacterial cell wall regulation and stress response pathways. With rising antibiotic resistance, characterizing PonA’s molecular mechanisms remains vital for developing targeted therapies against multidrug-resistant pathogens.
×
